HCB101

Other Medications

Description

HCB101 is an experimental medication currently being studied in clinical trials for advanced or metastatic colorectal cancer. It is being investigated in combination with standard treatments like Cetuximab, Bevacizumab, FOLFOX, and FOLFIRI. The goal of the trials is to determine the safety, tolerability, and potential effectiveness of HCB101 when added to these existing therapies. The trials are in the early phase (Phase 1b/IIa), meaning they primarily focus on safety and finding the right dose. HCB101 is given as an intravenous infusion once a week for the first three weeks of a 21-day cycle.

Mechanism of Action

The specific way HCB101 works (its mechanism of action) is still under investigation in clinical trials. It is being studied to see if it can improve the effectiveness of standard colorectal cancer treatments when used together.

Side Effects

As HCB101 is an experimental drug in early-phase trials The full range of potential side effects is still being evaluated. The primary focus of the current trials is to assess the safety and tolerability of HCB101 when combined with other medications. Information about specific side effects will become clearer as the trials progress.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT07204574 Phase 1

Recruiting

The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer

Taiwan

Quick Info

Category	Other Medications
Clinical Trials	1

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.